Volume | 396,134 |
|
|||||
News | - | ||||||
Day High | 3.16 | Low High |
|||||
Day Low | 2.95 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Acumen Pharmaceuticals Inc | ABOS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.07 | 2.95 | 3.16 | 2.98 | 3.05 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,133 | 396,134 | $ 3.00 | $ 1,190,106 | - | 1.8101 - 11.3099 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 7,206 | $ 2.98 | USD |
Acumen Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
171.99M | 57.91M | - | 0 | -52.37M | -0.90 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Acumen Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABOS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.61 | 3.61 | 2.95 | 3.24 | 231,361 | -0.63 | -17.45% |
1 Month | 3.31 | 3.92 | 2.95 | 3.49 | 177,149 | -0.33 | -9.97% |
3 Months | 4.50 | 4.60 | 2.95 | 3.73 | 254,851 | -1.52 | -33.78% |
6 Months | 2.27 | 5.09 | 2.21 | 3.58 | 359,534 | 0.71 | 31.28% |
1 Year | 4.87 | 11.3099 | 1.8101 | 5.66 | 569,222 | -1.89 | -38.81% |
3 Years | 25.07 | 26.98 | 1.8101 | 7.28 | 413,106 | -22.09 | -88.11% |
5 Years | 25.07 | 26.98 | 1.8101 | 7.28 | 413,106 | -22.09 | -88.11% |
Acumen Pharmaceuticals Description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. |